Clinical trials: Lung Cancer Small Cell Lung Cancer (SCLC)
Small Cell Lung Cancer, Gastric Adenocarcinoma
PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies
The purpose of this signal seeking study is to determine whether treatment with PDR001 and LAG525 demonstrates sufficient efficacy in advanced malignancies to warrant further study.
- Conditions
- Small Cell Lung Cancer, Gastric Adenocarcinoma, Esophageal Adenocarcinoma, Castration Resistant Prostate Adenocarcinoma
- Trial name
- NCT03365791
- Testing
- PDR001, LAG525
- Where
- 20 sites in United States
- Volunteers
- 76 people
- Sponsor
- Novartis Pharmaceuticals
Hematologic Malignancies, Solid Tumor
A Trial of PF-07901800 (TTI-621) for Patients With Hematologic Malignancies and Selected Solid Tumors
Multicenter, open-label, phase 1a/1b trial of PF-07901800 (TTI-621) in subjects with relapsed or refractory hematologic malignancies and selected solid tumors.
- Trial name
- NCT02663518
- Testing
- PF-0791800 (TTI-621), PF-07901800 (TTI-621) plus Rituximab, PF-07901800 (TTI-621) plus Nivolumab
- Where
- 51 sites in United States, Canada
- Volunteers
- 249 people
- Sponsor
- Pfizer
Spinal Tumor
A Prospective Study Using Implanted Fiducial Markers to Assess Treatment Accuracy and Esophageal Toxicity in Spinal Stereotactic Body Radiation Therapy
The goal of the first part of this clinical research study is to learn how to deliver more accurate radiation treatment of tumors in the spine.
- Trial name
- NCT01624220
- Testing
- Spinal SBRT (Standard Dose), Spinal SBRT (Higher Dose), Gold Seed Implantation
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- M.D. Anderson Cancer Center
Carcinoma, Non-Small-Cell Lung
A Study of Lazertinib in Participants With Epidermal Growth Factor Receptor (EGFR) Mutation Positive Advanced Non-Small Cell Lung Cancer (NSCLC)
The main purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics (PK) of Lazertinib when given orally to participants with epidermal growth factor receptor single activating mutation positive (EGFRm+)…
- Trial name
- NCT04075396
- Testing
- Lazertinib
- Where
- 9 sites in United States, Spain and 1 more
- Volunteers
- 29 people
- Sponsor
- Janssen Research & Development, LLC
Non-small Cell Lung Cancer
Cetuximab as Therapy for Recurrent Non-Small Cell Lung Cancer Patients Who Have Received Prior Therapy
The purpose of this research study is to find out how well cetuximab works in treating NSCLC in patients who have been previously treated with a class of drug called tyrosine kinase inhibitor (TKI).
- Trial name
- NCT00694603
- Testing
- Cetuximab
- Where
- 3 sites in United States
- Volunteers
- 56 people
- Sponsor
- Lecia V. Sequist
Lung Cancer, Nonsmall Cell, Lung Cancer Stage III
Induction Chemo-Nivo in Unresectable Stage III NSCLC
The purpose of this study is to determine the response rate, safety, and effectiveness of a combination therapy in patients with lung cancer.
- Trial name
- NCT06003075
- Testing
- Nivolumab and Chemotherapy, Nivolumab, Post Induction Surgery
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Ralph G Zinner
Stage IIIB Lung Non-Small Cell Cancer AJCC v7, Stage IV Non-Small Cell Lung Cancer AJCC v7
Sunitinib Malate as Maintenance Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer Previously Treated With Combination Chemotherapy
This randomized phase III trial studies sunitinib malate to see how well it works when given as maintenance therapy (meaning it is approved for treatment after chemotherapy) in patients with stage IIIB-IV non-small cell lung…
- Trial name
- NCT00693992
- Testing
- Laboratory Biomarker Analysis, Quality-of-Life Assessment, Sunitinib Malate
- Where
- 484 sites in United States
- Volunteers
- 210 people
- Sponsor
- National Cancer Institute (NCI)
Non-Small Cell Lung Cancer
A Study of Atezolizumab as Neoadjuvant and Adjuvant Therapy in Resectable Non-Small Cell Lung Cancer (NSCLC) - Lung Cancer Mutation Consortium (LCMC3)
This study was designed to evaluate the safety and efficacy of neoadjuvant and adjuvant atezolizumab in participants with resectable Non-Small Cell Lung Cancer (NSCLC).
- Trial name
- NCT02927301
- Testing
- Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody
- Where
- 19 sites in United States
- Volunteers
- 181 people
- Sponsor
- Genentech, Inc.
Non-small Cell Lung Cancer Stage III
NIvolumab COmbination With Standard First-line Chemotherapy and Radiotherapy in Locally Advanced Stage IIIA/B Non-Small Cell Lung Carcinoma
The aim of the study is to investigate the tolerability (how severe the side effects are) and the efficacy (how well the treatment works) when nivolumab is added to the current standard treatment (chemotherapy and radiotherapy)…
- Trial name
- NICOLAS (NCT02434081)
- Testing
- Nivolumab
- Where
- 11 sites in Belgium, Germany and 3 more
- Volunteers
- 94 people
- Sponsor
- ETOP IBCSG Partners Foundation
Extensive Stage Lung Small Cell Carcinoma
Olaparib, Cediranib Maleate, and Standard Chemotherapy in Treating Patients With Small Cell Lung Cancer
This phase II trial studies how well olaparib, cediranib maleate, and standard chemotherapy work in treating patients with small cell lung cancer.
- Trial name
- NCT02899728
- Testing
- Carboplatin, Cediranib, Cediranib Maleate
- Where
- 24 sites in United States
- Volunteers
- 9 people
- Sponsor
- National Cancer Institute (NCI)
Recurrent Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer
Carboplatin, Paclitaxel, and Bevacizumab With or Without Erlotinib Hydrochloride in Treating Non-Smokers With Advanced Non-Small Cell Lung Cancer
This randomized phase II trial studies how well carboplatin, paclitaxel, and bevacizumab work with or without erlotinib hydrochloride in treating non-smokers with advanced non-small cell lung cancer.
- Conditions
- Recurrent Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
- Trial name
- NCT00976677
- Testing
- erlotinib hydrochloride, paclitaxel, carboplatin
- Where
- 108 sites in United States
- Volunteers
- 10 people
- Sponsor
- National Cancer Institute (NCI)
Non-Small Cell Lung Cancer
Study of Pembrolizumab (MK-3475) Subcutaneous (SC) Versus Pembrolizumab Intravenous (IV) Administered With Platinum Doublet Chemotherapy in Participants With Metastatic Squamous or Nonsquamous Non-Small Cell Lung Cancer (NSCLC) (MK-3475-A86)
The purpose of this study is to evaluate pembrolizumab (MK-3475) subcutaneous (SC) administration as the first-line therapy in the treatment of metastatic squamous and nonsquamous NSCLC by assessing the pharmacokinetics (PK)…
- Trial name
- NCT04956692
- Testing
- Pembrolizumab SC, Pembrolizumab IV, Paclitaxel
- Where
- 126 sites in United States, Brazil and 14 more
- Volunteers
- 531 people
- Sponsor
- Merck Sharp & Dohme LLC
Carcinoma, Non-Small-Cell Lung
Progression Free Survival (PFS) Using Erlotinib for Non-Small-Cell Lung Cancer (NSCLC) in Chinese Population
This trial is an extension to ENSURE, a study of erlotinib versus gemcitabine/cisplatin combination chemotherapy as the first-line treatment for patients with non-small-cell lung cancer (NSCLC) with mutations in the tyrosine…
- Trial name
- NCT02000531
- Testing
- Erlotinib, Chemotherapy
- Where
- 11 sites in China
- Volunteers
- 45 people
- Sponsor
- Hoffmann-La Roche
Cachexia, Non-Small Cell Lung Cancer
Safety and Efficacy of Anamorelin HCl in Patients With Non-Small Cell Lung Cancer-Cachexia (ROMANA 2)
The administration of Anamorelin in patients with Stage III-IV non-small cell lung cancer-cachexia (NSCLC-C) is expected to increase appetite, lean body mass, weight gain, and muscle strength.
- Trial name
- NCT01387282
- Testing
- Anamorelin HCl
- Where
- 46 sites in United States, Australia and 5 more
- Volunteers
- 495 people
- Sponsor
- Helsinn Therapeutics (U.S.), Inc
Lung Cancer, Non Small Cell Lung Cancer
Phase II Study of Stereotactic Body Radiation Therapy Using Tomotherapy for Tumors of the Lung
The purpose of this study is to determine the response of lung tumors to radiation therapy. This study will be using a type of radiation therapy called tomotherapy.
- Conditions
- Lung Cancer, Non Small Cell Lung Cancer, Solid Tumors
- Trial name
- NCT00832780
- Testing
- Stereotactic Body Radiation
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- New Mexico Cancer Research Alliance
Non-Squamous Non-Small Cell Lung Cancer
A Study of Tarceva (Erlotinib) in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (TRIGGER)
This single-arm, open-label study evaluated the efficacy and safety of Tarceva (erlotinib) in participants with locally advanced or metastatic non-small cell lung cancer. Participants received daily oral doses of 150 mg Tarceva.
- Trial name
- NCT01378962
- Testing
- erlotinib
- Where
- 10 sites in Italy
- Volunteers
- 50 people
- Sponsor
- Hoffmann-La Roche
Advanced Non-squamous Non-Small Cell Lung Cancer
Dose Escalation of Bevacizumab With Ambulatory Blood Pressure Monitoring in Patients With Advanced Non-squamous NSCLC
The purpose of this study is to see if higher dose of bevacizumab can be taken safely by some patients and if changes in the dose of bevacizumab have any effect on blood pressure.
- Trial name
- AVF4759 (NCT01063283)
- Testing
- Pemetrexed, Carboplatin, Bevacizumab 7.5 mg/kg
- Where
- 3 sites in United States
- Volunteers
- 20 people
- Sponsor
- University of Chicago
Non-Small Cell Lung Cancer
ARCHER 1009 : A Study Of Dacomitinib (PF-00299804) Vs. Erlotinib In The Treatment Of Advanced Non-Small Cell Lung Cancer
This is a multinational, multicenter, randomized,double-blinded, Phase 3 study comparing the efficacy and safety of treatment with PF-00299804 to treatment with erlotinib in patients with advanced non-small cell lung cancer…
- Trial name
- ARCHER 1009 (NCT01360554)
- Testing
- Dacomitinib (PF-00299804), Active Comparator (erlotinib)
- Where
- 224 sites in United States, Austria and 21 more
- Volunteers
- 878 people
- Sponsor
- Pfizer
Non Small Cell Lung Cancer, Lung Cancer
Pharmacokinetic & Pharmacodynamic Study of ABT-751 With Carboplatin in Patients With Advanced Lung Cancer
Primary Objectives: The primary objectives of this study are as follows: To determine the dose limiting toxicity (DLT) and the maximum tolerated dose (MTD) of escalating ABT-751 in combination with fixed dose carboplatin in…
- Trial name
- NCT00735878
- Testing
- ABT-751 and Carboplatin
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Konstantin Dragnev
Advanced Stage Non-small Cell Lung Cancer
Evaluate the Mediators of Sensitivity and Resistance to Nivolumab Plus Ipilimumab in Patients With Advanced NSCLCs
The purpose of this study is to closely examine tumor and blood samples from patients treated with nivolumab and ipilimumab in order to try to identify why some patients with lung cancers respond and why some patients do not.
- Trial name
- NCT02350764
- Testing
- nivolumab, pilimumab
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.